Laboratory Corp of America Holdings has patented a method for non-invasive assessment of copy number alterations in a test subject’s circulating cell free nucleic acid. The method involves sequencing, probe enrichment, and variant calling to determine the presence or absence of copy number alterations. GlobalData’s report on Laboratory Corp of America Holdings gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Laboratory Corp of America Holdings, Molecular diagnosis biomarkers was a key innovation area identified from patents. Laboratory Corp of America Holdings's grant share as of February 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Non-invasive assessment of copy number alterations in nucleic acid
A recently granted patent (Publication Number: US11929143B2) discloses a method for determining the presence or absence of copy number alterations in a test subject. The method involves obtaining circulating cell-free nucleic acid from a test sample, ligating nucleic acid molecules with adapters to generate sequence constructs, enriching for genomic regions of interest using probe oligonucleotides, and sequencing the enriched library constructs. A computing system then generates alignment and probe computer files, followed by a variant call file to identify candidate variants and determine the presence of copy number alterations based on these variants. The method covers various genetic alterations, including single nucleotide variants, insertions, deletions, fusions, translocations, and copy number alterations.
Furthermore, the patent also describes a system and a non-transitory computer-readable storage medium for classifying copy number alterations in a test sample. The system includes processors and memory encoded with instructions to perform the method described above. The memory is configured to generate consensus sequences, determine sample read coverage, and normalize the data based on GC content. The non-transitory computer-readable storage medium stores instructions for obtaining sequence reads, generating alignment and probe computer files, and identifying candidate variants to classify copy number alterations. Additionally, a segmentation process is applied to identify segments based on the probe log 2 ratio for each probe oligonucleotide. Overall, the patent presents a comprehensive method and system for accurately determining copy number alterations in circulating cell-free nucleic acid samples, offering potential applications in diagnostic and research settings.
To know more about GlobalData’s detailed insights on Laboratory Corp of America Holdings, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
